S-Nitrosylation Therapy Study for COVID-19

I'm Interested!

Proof of Concept Safety Trial for S-Nitrosylation Therapy to Improve Oxygenation Status in Severe Covid-19 Patients Receiving Supplemental Oxygen Support

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Other Respiratory and Intrathoracic Organs, COVID-19

Study Purpose

ENO treatment has the potential to significantly improve the clinical management of patients with COVID-19 who are experiencing lung injury. In sum, ENO is a novel drug and its inhalation constitutes a unique therapeutic approach that has the potential to provide distinctive benefits to COVID-19 patients.

Principal Investigator
Robert Schilz DO

Department/Division
Medicine (Pulmonary and Critical Care Medicine)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: STUDY20210599
StudyID: 2021-0744
ClinicalTrials.gov: NCT04528771

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422